On February 13, 2026, 2026 Annual Conference of Xieli Group was grandly held at the Innovation Center of Pengzhou Shuanghu Science and Technology Park. All Xieli members gathered together to hug the Spring Festival and jointly depict the blueprint for the future.

The Group Chairman delivered a speech, reviewing the struggling journey of 2025 and envisioning the new chapter of 2026. 2025 was an extraordinary and breakthrough year in the development history of Xieli Group. Under a favorable business and regulatory environment, the Group strictly followed national laws, regulations and industry standards, successfully passed various review and inspection procedures, and obtained core qualification certificates for pharmaceutical enterprises. These achievements have laid a solid foundation for the Group's compliant operation and sustainable development. Led by the Group's management team, all employees united as one to overcome difficulties, achieving a doubling of both output value and sales volume, a year-on-year growth of nearly 30% in export volume, and the creation of more than 100 new jobs, which laid a solid foundation for the high-quality development in 2026.

In 2025, facing the complex and severe economic situation, Xieli Group focused on its core pharmaceutical business and achieved significant growth. With the successful acquisition of international certifications such as those from the US FDA and Japan PMDA, the Group's access to overseas markets has been continuously expanded, and its international market share and customer recognition have been steadily improved. The EHS department adhered to the bottom line of safety and environmental protection, improved the safety and environmental management system, and strengthened the defense line for production safety and employees' occupational health, providing solid support for the Group's compliant development. Relying on stable and reliable product quality and comprehensive compliance guarantees, the Group has become a trustworthy partner in the global pharmaceutical industry chain.

In 2025, the Group always adhered to the concept of "people-oriented" , continuously optimized the salary and welfare system, carried out hierarchical and classified skill training, promoted job competition and career planning guidance, and built a growth platform for employees.

In 2025, a bunch of outstanding advanced individuals and teams emerged in the Group. The conference grandly commended these advanced teams and individuals, paying tribute to every effort and persistence, and taking the power of role models to lead the new journey and inspire further progress.

At the conference site, a signing ceremony for the 2026 target letter was also grandly held. Representatives of various departments and teams stepped onto the stage solemnly to sign the target letters and make solemn commitment, breaking down the Group's grand blueprint for 2026 into specific tasks and assigning responsibilities to each position. All employees simultaneously signed performance commitments, focusing on their own duties and fulfilling their responsibilities, which gathered a strong joint force of "everyone has goals, everyone has responsibilities, and everything is implemented".

2026 is the first year of the "15th Five-Year Plan" and a crucial year for Xieli Group to ride the momentum and continue its glory. The Chairman emphasized in his speech that in the new year, the Group will strengthen confidence and take practical measures to increase investment in technological transformation and innovation, expand production capacity, explore markets, reduce costs and increase efficiency, further promote intelligent and digital transformation, and lead all members of Xieli to continue their struggles and jointly write a new chapter of high-quality and leapfrog development.
